For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

Understanding mechanisms of progression for Prostate Cancer

Once exposed to hormonal therapy, prostate cancer may develop resistance by becoming AR negative

Mechanisms of progression of prostate cancer may include adaptation and selection1:

Men with metastatic castration-resistant prostate cancer (mCRPC) may develop therapeutic resistance2-4

Therapeutic resistance can present 2 different ways:

  • Primary resistance (patients are initially refractory to therapy)
  • Acquired resistance (patients develop resistance several months after treatment is initiated)

Treatment Resistance



  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave

You are leaving to view another Sanofi Genzyme Corporation website.